FDA APPROVED INDICATIONS OF SETRA

• Major Depressive Disorder
• Panic Disorder
• Pre-menstrual Dysphoric disorder
• Post traumatic stress disorder
• Social Anxiety Disorder
• Obsessive Complusive Disorder 

PHARMAKOKINETIC OF SETRA

Absorption : Mean peak plasma concentrations occurred between 4.5 to 8.4 hours. The steady-state concentrations are reached after 1 week following once-daily administration. May be taken with or without food. Protein Binding : Highly bound to serum protein (98%)  Metabolism : Extensively metabolized in the liver. Sertraline metabolism involves N-demethylation, N-hydroxylation, oxidative deamination, and glucuronidation of sertraline carbamic acid. N-desmethylsertraline to be substantially less active than sertraline. Route of Elimination : Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination. Half Life: The elimination half-life of sertraline is approximately 25-26 hours.

PREGNANCY CATEGORY   : C

 CONTRAINDICATIONS

• In patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated
• In patients with a hypersensitivity to sertraline or any of the inactive ingredients